We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A 90-year-old woman was referred by her ...
Please provide your email address to receive an email when new articles are posted on . A 78-year-old woman was referred to the neuro-ophthalmology service at New England Eye Center for several months ...
We observed 13 patients who developed a subsequent increase in exophthalmometry measurements in the non-proptotic eye within a period ranging from 6 months to 7 years. We believe that such a variable ...
Findings showed a statistically significant reduction in proptosis in the linsitinib 150mg twice daily group, with a proptosis responder rate of 52% at week 24. Topline results were announced from a ...
Winner of the Synthes Skull Base Award, William T. Couldwell, MD, PhD, FAANS, presented findings from the study, Outcomes after Surgical Treatment of Meningioma-associated Proptosis, during the 83rd ...
Findings from THRIVE showed treatment with veligrotug led to statistically significant improvements in the signs and symptoms of TED. Topline data were announced from a phase 3 study evaluating ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
Hosted on MSN
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial
Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 ...
Of the 655 patients enrolled in this study, 89 (13.5%) (95% confidence interval [CI] 15%-10%) presented with unilateral exophthalmos. Exophthalmometer values in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback